Cantor’s Mara Goldstein says growth beyond 2020 for CELG just got cloudy with the FDA’s RTF letter for ozanimod.
Canaccord’s Michael Graham is only waiting to bet on SQ until he spots a more advantageous entry point.
Rosenblatt’s Hans Mosesmann says AMD has good odds for the notebooks and servers markets, GBH Insights’ Daniel Ives cheers AAPL shares are “back on track” after rocky FQ2 guidance fears.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is scheduled to report its fourth-quarter earnings tomorrow morning, and H.C.
Oppenheimer hasn’t left the bullish camp on either LL nor FIT just yet; analysts make compelling cases to back these two market losers today.
By 2019, Ives is bullish that AMZN can hit trillion-dollar valuation; here’s why.
Canaccord’s Neil Maruoka jumps up his price target on VRX, but even with more optimism, still angles for 5% downside potential from the stock.
Gautam Khanna cuts his price target on GE as he shares cautious takeaways from the 10K release.
GBH Insights’ Daniel Ives notes that as some investors worry about the FB News Feed variable, TWTR gains footing.
After an impressive rebound, can Square Inc (NYSE:SQ) stock maintain its momentum? If you ask RBC Capital’s top analyst Daniel Perlin the answer is clearly: Yes.